Q3 EPS Estimate for Acadia Healthcare Lowered by Analyst

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) – Equities researchers at Zacks Research reduced their Q3 2026 earnings per share (EPS) estimates for shares of Acadia Healthcare in a research note issued on Tuesday, August 11th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $0.46 for the quarter, down from their previous estimate of $0.49. The consensus estimate for Acadia Healthcare’s current full-year earnings is $1.54 per share. Zacks Research also issued estimates for Acadia Healthcare’s Q4 2026 earnings at $0.27 EPS, FY2026 earnings at $1.48 EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $0.41 EPS, Q3 2027 earnings at $0.57 EPS, Q4 2027 earnings at $0.43 EPS, FY2027 earnings at $1.68 EPS, Q1 2028 earnings at $0.33 EPS, Q2 2028 earnings at $0.51 EPS and FY2028 earnings at $1.96 EPS.

Other equities analysts have also recently issued reports about the stock. Royal Bank Of Canada raised their target price on shares of Acadia Healthcare from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Monday, May 4th. UBS Group increased their price objective on shares of Acadia Healthcare from $31.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, July 9th. TD Cowen lifted their price objective on Acadia Healthcare from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. KeyCorp boosted their target price on shares of Acadia Healthcare from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Finally, Jefferies Financial Group upgraded Acadia Healthcare from a “hold” rating to a “buy” rating and lifted their target price for the stock from $24.50 to $30.00 in a report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $29.85.

Acadia Healthcare Price Performance

ACHC stock opened at $31.10 on Wednesday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.57 and a current ratio of 1.57. The company’s fifty day moving average price is $29.32 and its 200-day moving average price is $24.74. Acadia Healthcare has a one year low of $11.43 and a one year high of $35.83. The company has a market capitalization of $2.90 billion, a PE ratio of -2.50, a price-to-earnings-growth ratio of 10.31 and a beta of 0.64.

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.03. Acadia Healthcare had a positive return on equity of 6.19% and a negative net margin of 33.44%.The business had revenue of $865.84 million during the quarter, compared to the consensus estimate of $844.19 million. During the same period in the prior year, the company posted $0.83 EPS. The firm’s revenue for the quarter was down .4% compared to the same quarter last year. Acadia Healthcare has set its FY 2026 guidance at 1.450-1.600 EPS.

Institutional Trading of Acadia Healthcare

Several institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Acadia Healthcare in the first quarter worth approximately $1,600,000. Goldman Sachs Group Inc. lifted its stake in shares of Acadia Healthcare by 21.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 698,225 shares of the company’s stock worth $21,170,000 after acquiring an additional 121,444 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Acadia Healthcare by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 340,916 shares of the company’s stock valued at $10,337,000 after acquiring an additional 27,207 shares during the period. American Century Companies Inc. grew its position in Acadia Healthcare by 531.5% in the 2nd quarter. American Century Companies Inc. now owns 105,739 shares of the company’s stock valued at $2,399,000 after acquiring an additional 88,995 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in Acadia Healthcare by 21.9% in the second quarter. Prudential Financial Inc. now owns 9,903 shares of the company’s stock worth $225,000 after purchasing an additional 1,780 shares during the period.

Key Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Zacks Research raised several EPS forecasts. Estimates increased for fiscal 2026 to $1.48 from $1.46, fiscal 2027 to $1.68 from $1.63, and fiscal 2028 to $1.96 from $1.76. Analysts also raised forecasts for Q4 2026, Q1 and Q3 2027, Q1 and Q2 2028, and Q4 2027. The revisions suggest improved longer-term earnings potential and may support investor sentiment.
• Neutral Sentiment: The outlook remains below some consensus expectations in the near term. Zacks’ $1.48 fiscal 2026 estimate is below the broader consensus of $1.54, although its fiscal 2027 and fiscal 2028 forecasts point to accelerating earnings growth. Acadia’s latest quarterly results showed revenue of $865.8 million and adjusted EPS of $0.38, exceeding analyst expectations, but revenue declined slightly year over year.
• Neutral Sentiment: The reported short-interest data appears unreliable. The filing lists short interest at zero shares, a zero-day short-interest ratio, and an undefined percentage change despite describing a “large increase.” As a result, it provides no meaningful indication of short-seller positioning.
• Negative Sentiment: Near-term estimates were also cut. Zacks reduced its Q3 2026 EPS forecast to $0.46 from $0.49 and its Q2 2027 estimate to $0.41 from $0.45. These reductions could temper enthusiasm about immediate earnings momentum.
• Negative Sentiment: Regulatory and legal uncertainty remains an overhang. Kahn Swick & Foti said it is continuing an investigation into Acadia’s officers and directors following the company’s disclosure of a voluntary information request from the U.S. Attorney’s Office for the Southern District of New York and a federal grand-jury subpoena. The investigation could increase legal costs and uncertainty around the company. Acadia Healthcare Investigation Continued

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.